Tempus operates an AI-powered precision medicine platform focused on oncology and other disease areas. By aggregating clinical, molecular, and real-world data, Tempus applies machine learning to generate actionable insights that help physicians personalize treatment strategies.
Its platform bridges bioinformatics, pathology, genomics, and clinical workflows—enabling hospitals, researchers, and biopharma companies to accelerate biomarker discovery, enhance trial design, and ultimately improve patient outcomes.
What Is Tempus and What Does It Do?
Tempus, founded in 2015 by Eric Lefkofsky, is an AI-based precision medicine provider for oncology headquartered in Chicago, United States.
Tempus employs 772 people as of December 2022 and the company builds a comprehensive informatics platform that analyzes genomic and clinical data to guide cancer treatment. Its tools offer decision support for physicians, data insights for life sciences companies, and advanced analytics for developing targeted therapies and improving clinical workflows.
How Much Funding Has Tempus Raised?
1. Series G
• Amount Raised: $200M
• Date: December 2020
• Lead Investors: Google, Novo Holdings, Baillie Gifford, Franklin Templeton Investments, T. Rowe Price
• Motivation: To scale clinical data infrastructure, enhance AI models, and support commercialization across oncology and emerging therapeutic areas.
Total Funding Raised: $1.05 Billion
Current Valuation: $8.1 Billion (as of December 2020)
Latest Funding Date: October, 2022
Key Investors
1. T. Rowe Price
• Details: A global investment manager active in late-stage growth companies.
• Investment Focus Areas: Public equities, private tech, and healthcare.
• Notable Investments: Tempus, Zoom, Moderna.
2. Baillie Gifford
• Details: A long-term growth-focused investment firm.
• Investment Focus Areas: Disruptive innovation across technology and healthcare.
• Notable Investments: Tesla, Amazon, Tempus.
Where Is Tempus’s Headquarters?
Tempus is headquartered in Chicago, United States one of the country’s leading hubs for healthcare research, clinical institutions, and data science talent. The location supports close collaboration with hospitals, universities, and life sciences partners.
What’s Next for Tempus?
Tempus is expected to expand beyond oncology into additional therapeutic areas, advance its AI-driven diagnostics, and deepen collaborations with biopharma companies for drug discovery and clinical trial optimization. With strong investor backing and a multibillion-dollar valuation, Tempus is positioned to become central infrastructure for data-driven, personalized medicine.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like Tempus. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.
